Infectious Disease

Top Story

FDA grants orphan drug designation to SER-109 for preventing recurrent C. difficile infection

August 31, 2015

The FDA has granted orphan drug designation to SER-109, an oral therapeutic in development for the prevention of recurrent Clostridium difficile infection in adult patients, the manufacturer announced.

According to a press release, a single dose of four SER-109 (Seres Therapeutics) capsules “reintroduces an ecology of purified bacterial spores which restore the microbiome to a healthy state” from a dysbiotic state, which may be induced or prolonged by antibiotics, which are currently the only FDA-approved treatment option for recurrent C. difficile infection.

In the Journals

HBV prevalence in rural Chinese men declines to 'intermediate endemic'

August 31, 2015
Updated baseline data suggest the prevalence of hepatitis B virus infection in men in rural China changed from highly endemic in 2006 to intermediate endemic in 2012…
In the Journals

Low vitamin D levels prevalent in untreated patients with HBV

August 31, 2015
In a new study, researchers found that untreated patients with chronic hepatitis B virus infection had significantly low levels of vitamin D.“Given the paucity of…

Ascletis launches phase 2 trial of interferon-free regimen for HCV

August 31, 2015
Ascletis Pharmaceuticals Co., Ltd. announced the launch of a phase 2 clinical trial in Taiwan to investigate the efficacy of its interferon-free regimen for the…
Carlos del-Rio In the Journals

Key barriers block widespread protection with PrEP

August 31, 2015
Despite the potential of HIV pre-exposure prophylaxis, several barriers make it ineffective at the individual and population levels, according to researchers at Emory…
More News Headlines »
CME
Infectious Disease Case Consults

The Patient with Conjunctivitis

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with conjunctivitis.
More »
At Issue Video
VIDEO: Cure is ‘next frontier’ of HIV

VIDEO: Cure is ‘next frontier’ of HIV

July 1, 2015
Timothy Brown – the Berlin patient – has led researchers to the next frontier of HIV research, according to…
More »
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
morganatic-roan